Brinker Capital Investments LLC Acquires 150 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Brinker Capital Investments LLC Acquires 150 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Brinker Capital Investments LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,297 shares of the biotechnology company's stock after buying an additional 150 shares during the period. Brinker Capital Investments LLC's holdings in Sarepta Therapeutics were worth $475,000 at the end of the most recent reporting period.
Brinker Capital Investments LLC在最近提交给美国证券交易委员会的13F文件中称，该公司第三季度增持了Sarepta Treateutics，Inc.(纳斯达克代码：SRPT-GET Rating)的股份3.6%。该基金持有这家生物技术公司的4297股股票，在此期间又购买了150股。在最近一个报告期结束时，Brinker Capital Investments LLC在Sarepta Treeutics持有的股份价值47.5万美元。
A number of other large investors have also recently made changes to their positions in the business. Great West Life Assurance Co. Can increased its holdings in shares of Sarepta Therapeutics by 126.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 10,774 shares of the biotechnology company's stock worth $1,187,000 after buying an additional 6,011 shares during the last quarter. M&G Investment Management Ltd. bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $1,719,000. Dupont Capital Management Corp grew its holdings in Sarepta Therapeutics by 70.1% during the 3rd quarter. Dupont Capital Management Corp now owns 7,554 shares of the biotechnology company's stock valued at $835,000 after purchasing an additional 3,114 shares during the last quarter. NJ State Employees Deferred Compensation Plan bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $763,000. Finally, EFG Asset Management North America Corp. bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $2,364,000. 87.31% of the stock is currently owned by institutional investors.
其他一些大型投资者最近也改变了他们在该业务中的头寸。大西部人寿保险公司可以在第三季度增持Sarepta Treeutics的股票126.2%。大西部人寿保险公司现在拥有10,774股这家生物技术公司的股票，价值1,187,000美元，此前在上个季度又购买了6,011股。M&G投资管理有限公司在第三季度购买了Sarepta Treeutics的一个新头寸，价值约1,719,000美元。杜邦资本管理公司在第三季度增持了Sarepta Treateutics 70.1%的股份。杜邦资本管理公司(DuPont Capital Management Corp)目前持有这家生物技术公司7554股股票，价值83.5万美元，此前该公司在上个季度又购买了3114股。新泽西州雇员延期补偿计划在第三季度购买了Sarepta治疗公司的一个新头寸，价值约763,000美元。最后，EFG资产管理北美公司在第三季度购买了Sarepta治疗公司的一个新头寸，价值约2,364,000美元。87.31%的股票目前由机构投资者持有。
Insider Transactions at Sarepta Therapeutics
Sarepta治疗公司的内幕交易
In other news, Director Stephen Mayo sold 858 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $109.92, for a total value of $94,311.36. Following the completion of the sale, the director now owns 6,387 shares of the company's stock, valued at approximately $702,059.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.40% of the company's stock.
在其他新闻方面，董事斯蒂芬·梅奥在11月17日(星期四)的一笔交易中出售了858股该公司股票。这些股票的平均价格为109.92美元，总价值为94,311.36美元。出售完成后，董事现在拥有该公司6,387股股票，价值约702,059.04美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。公司内部人士持有该公司6.40%的股份。
Sarepta Therapeutics Price Performance
Sarepta治疗公司的价格表现
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($1.73). Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The business had revenue of $230.30 million during the quarter, compared to analysts' expectations of $234.55 million. During the same period in the previous year, the company posted ($0.60) EPS. Sarepta Therapeutics's revenue for the quarter was up 21.6% on a year-over-year basis. Equities analysts predict that Sarepta Therapeutics, Inc. will post -8.09 earnings per share for the current fiscal year.
赛瑞普塔治疗公司(纳斯达克代码：SRPT-GET Rating)上一次公布季度收益是在11月2日星期三。这家生物技术公司公布了本季度每股收益(2.94美元)，低于普遍预期的(1.21美元)和(1.73美元)。Sarepta Treeutics的净资产回报率为负97.37%，净利润率为负81.76%。该业务本季度营收为2.303亿美元，高于分析师预期的2.3455亿美元。去年同期，该公司公布了每股收益(0.60美元)。Sarepta Treateutics本季度的收入同比增长21.6%。股票分析师预测，Sarepta治疗公司将公布本财年每股收益为8.09美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities analysts recently commented on SRPT shares. StockNews.com started coverage on shares of Sarepta Therapeutics in a report on Wednesday, October 12th. They set a "hold" rating on the stock. Morgan Stanley upped their price target on shares of Sarepta Therapeutics from $135.00 to $141.00 and gave the company an "equal weight" rating in a report on Thursday, October 13th. UBS Group upgraded shares of Sarepta Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $100.00 to $158.00 in a report on Friday, December 16th. The Goldman Sachs Group upped their price target on shares of Sarepta Therapeutics from $152.00 to $171.00 and gave the company a "buy" rating in a report on Thursday, November 3rd. Finally, Cowen upped their price target on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $150.14.
几位股票分析师最近对SRPT的股票发表了评论。StockNews.com在10月12日星期三的一份报告中开始对Sarepta治疗公司的股票进行报道。他们对该股设定了“持有”评级。在10月13日周四的一份报告中，摩根士丹利将赛瑞普塔治疗公司的股票目标价从135.00美元上调至141.00美元，并给予该公司“同等权重”的评级。瑞银集团在上周五的一份报告中将赛瑞普塔治疗公司的股票评级从中性上调至买入，并将该公司的目标价从100.00美元上调至158.00美元。高盛夫妇在11月3日周四的一份报告中将赛瑞普塔治疗公司的股票目标价从152.00美元上调至171.00美元，并给予该公司“买入”评级。最后，考恩在1月11日星期三的一份报告中将Sarepta治疗公司的股票目标价从114.00美元上调至125.00美元。三名研究分析师对该股的评级为持有，七名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该公司的共识评级为“适度买入”，共识目标价为150.14美元。
About Sarepta Therapeutics
关于Sarepta Treateutics
(Get Rating)
(获取评级)
Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Sarepta治疗公司是一家商业阶段的生物制药公司，致力于发现和开发治疗罕见疾病的疗法。该公司成立于1980年7月22日，总部设在马萨诸塞州剑桥市。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
- 免费获取StockNews.com关于Sarepta治疗(SRPT)的研究报告
- 柔顺治疗公司的差距增加了34%：未来还会有更多的好处吗？
- 2023年初裁员将如何影响这5只生物科技股？
- Baudax Bio投资者在经历了70%的飙升后，痛苦是否已经结束？
- 火箭实验室的首次美国发射将把斯托克送入平流层吗？
- Crane Holdings什么时候起飞？
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Sarepta治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Sarepta治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。